First in Series Virtual Roundtable with Illumina on Understanding Drug Resistance

On December 5, 2024, Illumina in partnership with NTRKers Foundation, Inc., hosted a first in series virtual roundtable.

This session included an insightful discussion exploring the critical concept of drug therapy resistance in patients with cancer, driven by NTRK gene fusions. Patients and caregivers were able to join virtually and learn what therapy resistance is, why it occurs, and how it could impact the treatment journey. Interactive dialogue included an opportunity for questions.

The informational slides presented during the virtual roundtable are available for viewing HERE.